Redeye provides an initial take following Senzime’s Q3 2025 report. Sales came in slightly below expectations, while EBIT was in line. Overall, the report contained no major surprises. We will publish a research update shortly, where we expect to make only minor downward adjustments to our estimates, leaving our valuation of Senzime unchanged.
LÄS MER
